skip to content


Issue No. 14 | May 17, 2013

News and Features

May 18 is HIV Vaccine Awareness Day

Research to develop a safe and effective HIV vaccine is advancing because of the combined efforts of volunteers, community members, health professionals, and scientists across the nation and the world. To recognize their efforts, the nation observes HIV Vaccine Awareness Day on May 18.

Explore the links on our HIV Vaccine Awareness Day webpage [en español] to learn more about this observance and HIV vaccine research that is currently in progress.

May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day

May 19 is set aside each year to observe National Asian and Pacific Islander HIV/AIDS Awareness Day. The annual observance was founded by the Banyan Tree Project, with support from the Centers for Disease Control and Prevention (CDC). The goal of the project is to stop HIV/AIDS-related stigma in Asian and Pacific Islander communities. In the words of the Banyan Tree Project, “… this type of discrimination prevents A&PIs [Asians and Pacific Islanders] from getting tested for HIV and from getting health care and other services they need to stay healthy.”

Browse the links on our National Asian and Pacific Islander HIV/AIDS Awareness Day webpage [en español] to learn more about the observance and find related information.

Recent HIV/AIDS News from NIAID and FDA

  • May 9, 2013: NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies

    “A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research.”

    Read the NIAID press release.
  • May 13, 2013: FDA Announces Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research

    “On June 14, 2013, as part of the Patient-Focused Drug Development initiative intended to enhance patient input, FDA will be hosting a public meeting on human immunodeficiency virus (HIV) Patient-Focused Drug Development and HIV Cure Research. FDA is interested in obtaining patient input on the impact of HIV on daily life and currently available therapies to treat the condition (topic 1), and patients’ views on issues related to HIV cure research (topic 2).” 

    Read the FDA meeting announcement.
  • May 14, 2013: Regulatory Officials Informed of HVTN 503 HIV Vaccine Trial Findings

    “Officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the NIAID-funded HIV Vaccine Trials Network (HVTN), and study investigators have recently informed the appropriate regulatory authorities in South Africa and the United States of findings from their follow-up analysis of the HVTN 503 “Phambili” HIV vaccine clinical trial in South Africa. This trial was terminated in September 2007 as a precaution after a different trial (the “Step” Study) involving the same candidate vaccine was stopped because of a higher risk of HIV acquisition among participants who received the study vaccine.”

    Read the NIAID bulletin.